Epcoritamab for Marginal Zone Lymphoma

Recruiting in Palo Alto (17 mi)

Overseen by Izidore Lossos, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Izidore Lossos, MD

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The purpose of this study is to assess if an investigational treatment of Epcoritamab will be beneficial for patients with Marginal Zone Lymphoma (MZL).

Research Team

Izidore Lossos, MD

Principal Investigator

University of Miami

Eligibility Criteria

This trial is for patients with a diagnosis of Marginal Zone Lymphoma (MZL), which includes different subtypes like Splenic, MALT, and Nodal MZL. Specific eligibility criteria are not provided.

Inclusion Criteria

Ability to comply with the trial protocol

Able and willing to sign the informed consent form (ICF)

I have a specific type of marginal zone lymphoma.

Exclusion Criteria

My condition has progressed to diffuse large B-cell lymphoma.

I have had brain lymphoma or cancer spread to the lining of my brain.

I am currently being treated for a long-term or active infection.

Treatment Details

Interventions

• Epcoritamab (Monoclonal Antibodies)

Trial Overview The study is testing the effectiveness of Epcoritamab in treating newly diagnosed patients with Marginal Zone Lymphoma. It aims to determine if this investigational treatment can benefit those affected by MZL.

Participant Groups

Group I: Epcoritamab Group Experimental Treatment 1 Intervention

Participants will receive up to 12 cycles of Epcoritamab therapy, each cycle lasting 28 days. Total participation is up to 3 years.

Who Is Running the Clinical Trial?

Izidore Lossos, MD

Lead Sponsor

Trials

2

Recruited

60+

AbbVie

Industry Sponsor

Trials

1,079

Recruited

535,000+

Founded

2013

Headquarters

North Chicago, USA

Known For

Immunology treatments

Top Products

Humira (adalimumab), Skyrizi (risankizumab), Rinvoq (upadacitinib)

Dr. Roopal Thakkar

AbbVie

Chief Medical Officer since 2023

MD from Wayne State University School of Medicine

Robert A. Michael

AbbVie

Chief Executive Officer

Bachelor's degree in Finance from the University of Illinois

Genmab

Industry Sponsor

Trials

76

Recruited

15,300+

Dr. Jan van de Winkel

Genmab

Chief Executive Officer since 2010

PhD in Immunology, University of Utrecht

Dr. Judith Klimovsky

Genmab

Chief Medical Officer since 2019

MD, University of Copenhagen